ArticleVaccine2013
Tim-3 alters the balance of IL-12/IL-23 and drives TH17 cells: role in hepatitis B vaccine failure during hepatitis C infection.
Article in Vaccine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Is there a relationship between psoriasis and hepatitis C? A meta-analysis and bioinformatics investigation.Virology journal · 2021Pooled it
- Quantitative assessment of TIM-3 polymorphisms and cancer risk in Chinese Han population.Oncotarget · 2016Pooled it
- Overview of Hepatitis B Vaccine Non-Response and Associated B Cell Amnesia: A Scoping Review.Pathogens (Basel, Switzerland) · 2024Article
- Immunological factors linked to geographical variation in vaccine responses.Nature reviews. Immunology · 2024Review
- Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment.Molecular cancer · 2023Review
- Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma.Cancer drug resistance (Alhambra, Calif.) · 2023Review
- Oxidative Stress Induces Mitochondrial Compromise in CD4 T Cells From Chronically HCV-Infected Individuals.Frontiers in immunology · 2021Article
- Detection of Immune Checkpoint Receptors - A Current Challenge in Clinical Flow Cytometry.Frontiers in immunology · 2021Review
- Immune Checkpoints in Viral Infections.Viruses · 2020Review
- Regulation of Monocyte-Macrophage Responses in Cirrhosis-Role of Innate Immune Programming and Checkpoint Receptors.Frontiers in immunology · 2019Review
- Inhibition of TRF2 accelerates telomere attrition and DNA damage in naïve CD4 T cells during HCV infection.Cell death & disease · 2018Article
- Insufficiency of DNA repair enzyme ATM promotes naive CD4 T-cell loss in chronic hepatitis C virus infection.Cell discovery · 2018Article
- HCV-associated exosomes promote myeloid-derived suppressor cell expansion via inhibiting miR-124 to regulate T follicular cell differentiation and function.Cell discovery · 2018Article
- Tim-3 and its role in regulating anti-tumor immunity.Immunological reviews · 2017Review
- Unsolved problems and future perspectives of hepatitis B virus vaccination.World journal of gastroenterology · 2015Review
- Hepatitis C virus-induced reduction in miR-181a impairs CD4(+) T-cell responses through overexpression of DUSP6.Hepatology (Baltimore, Md.) · 2015Article
- Interleukin 12: still a promising candidate for tumor immunotherapy?Cancer immunology, immunotherapy : CII · 2014Review
- KLRG1 impairs CD4+ T cell responses via p16ink4a and p27kip1 pathways: role in hepatitis B vaccine failure in individuals with hepatitis C virus infection.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Th17 cells in autoimmune and infectious diseases.International journal of inflammation · 2014Review
- Tim-3: an activation marker and activation limiter of innate immune cells.Frontiers in immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Hepatitis B virus (HBV) vaccination is recommended for individuals with hepatitis C virus (HCV) infection given their shared risk factors and increased liver-related morbidity and mortality upon super-infection. Vaccine responses in this setting are often blunted, with poor response rates to HBV vaccinations in chronically HCV-infected individuals compared to healthy subjects. In this study, we investigated the role of T cell immunoglobulin mucin domain-3 (Tim-3)-mediated immune regulation in HBV vaccine responses during HCV infection. We found that Tim-3, a marker for T cell exhaustion, was over-expressed on monocytes, leading to a differential regulation of IL-12/IL-23 production which in turn TH17 cell accumulation, in HCV-infected HBV vaccine non-responders compared to HCV-infected HBV vaccine responders or healthy subjects (HS). Importantly, ex vivo blockade of Tim-3 signaling corrected the imbalance of IL-12/IL-23 as well as the IL-17 bias observed in HBV vaccine non-responders during HCV infection. These results suggest that Tim-3-mediated dysregulation of innate to adaptive immune responses is involved in HBV vaccine failure in individuals with chronic HCV infection, raising the possibility that blocking this negative signaling pathway might improve the success rate of HBV immunization in the setting of chronic viral infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.